Literature DB >> 16873543

Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity.

En-Ju D Lin1, Amanda Sainsbury, Nicola J Lee, Dana Boey, Michelle Couzens, Ronaldo Enriquez, Katy Slack, Ross Bland, Matthew J During, Herbert Herzog.   

Abstract

Neuropeptide Y (NPY) is a key regulator of energy homeostasis and is implicated in the development of obesity and type 2 diabetes. Whereas it is known that hypothalamic administration of exogenous NPY peptides leads to increased body weight gain, hyperphagia, and many hormonal and metabolic changes characteristic of an obesity syndrome, the Y receptor(s) mediating these effects is disputed and unclear. To investigate the role of different Y receptors in the NPY-induced obesity syndrome, we used recombinant adeno-associated viral vector to overexpress NPY in mice deficient of selective single or multiple Y receptors (including Y1, Y2, and Y4). Results from this study demonstrated that long-term hypothalamic overexpression of NPY lead to marked hyperphagia, hypogonadism, body weight gain, enhanced adipose tissue accumulation, hyperinsulinemia, and other hormonal changes characteristic of an obesity syndrome. NPY-induced hyperphagia, hypogonadism, and obesity syndrome persisted in all genotypes studied (Y1(-/-), Y2(-/-), Y2Y4(-/-), and Y1Y2Y4(-/-) mice). However, triple deletion of Y1, Y2, and Y4 receptors prevented NPY-induced hyperinsulinemia. These findings suggest that Y1, Y2, and Y4 receptors under this condition are not crucially involved in NPY's hyperphagic, hypogonadal, and obesogenic effects, but they are responsible for the central regulation of circulating insulin levels by NPY.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873543     DOI: 10.1210/en.2006-0097

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

2.  Y2 and Y4 receptor signalling attenuates the skeletal response of central NPY.

Authors:  Nicola J Lee; Susan Allison; Ronaldo F Enriquez; Amanda Sainsbury; Herbert Herzog; Paul A Baldock
Journal:  J Mol Neurosci       Date:  2010-07-16       Impact factor: 3.444

3.  Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion.

Authors:  John M Stafford; Fang Yu; Richard Printz; Alyssa H Hasty; Larry L Swift; Kevin D Niswender
Journal:  Diabetes       Date:  2008-03-10       Impact factor: 9.461

4.  Genome-wide association study suggested copy number variation may be associated with body mass index in the Chinese population.

Authors:  Bao-Yong Sha; Tie-Lin Yang; Lan-Juan Zhao; Xiang-Ding Chen; Yan Guo; Yuan Chen; Feng Pan; Zhi-Xin Zhang; Shan-Shan Dong; Xiang-Hong Xu; Hong-Wen Deng
Journal:  J Hum Genet       Date:  2009-02-20       Impact factor: 3.172

Review 5.  Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation.

Authors:  Satya P Kalra
Journal:  Peptides       Date:  2009-08-06       Impact factor: 3.750

Review 6.  Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: new therapeutic approaches.

Authors:  Satya P Kalra
Journal:  Nutrition       Date:  2008-09       Impact factor: 4.008

Review 7.  Central leptin insufficiency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions.

Authors:  Satya P Kalra
Journal:  Peptides       Date:  2007-10-24       Impact factor: 3.750

8.  NPY signalling in early osteoblasts controls glucose homeostasis.

Authors:  Nicola J Lee; Amy D Nguyen; Ronaldo F Enriquez; Jude Luzuriaga; Mohammed Bensellam; Ross Laybutt; Paul A Baldock; Herbert Herzog
Journal:  Mol Metab       Date:  2015-01-16       Impact factor: 7.422

9.  Genome-wide microRNA screening reveals that the evolutionary conserved miR-9a regulates body growth by targeting sNPFR1/NPYR.

Authors:  Yoon Seok Suh; Shreelatha Bhat; Seung-Hyun Hong; Minjung Shin; Suhyoung Bahk; Kyung Sang Cho; Seung-Whan Kim; Kyu-Sun Lee; Young-Joon Kim; Walton D Jones; Kweon Yu
Journal:  Nat Commun       Date:  2015-07-03       Impact factor: 14.919

Review 10.  Neuropeptide Y and Metabolism Syndrome: An Update on Perspectives of Clinical Therapeutic Intervention Strategies.

Authors:  Yinqiong Huang; Xiahong Lin; Shu Lin
Journal:  Front Cell Dev Biol       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.